Radiotheranostics Focus OncoOne specializes in radiotheranostics for cancer and autoimmune diseases, presenting a clear opportunity to position companion diagnostics and radiopharmaceutical collaborations with CROs, pharma partners, and academic centers pursuing targeted radiopharmaceutical therapies.

Strategic Partnerships Past collaborations with GenScript ProBio and engagement with major conferences suggest a readiness to form strategic manufacturing and development partnerships, enabling sales reps to target contract manufacturing and early-access programs.

Clinical Pipeline Lead candidate ON203 and radiodiagnostic 89 Zr-ON102 indicate a integrated theranostics platform with potential for co-development deals, license agreements, or milestone-driven collaborations with oncology and immunology programs.

Global Outreach Active participation in international events (SNMMI, TRP Summit) and a European base imply opportunities to pursue multinational collaborations, regulatory support, and cross-border trials to scale quickly.

Funding Readiness Recent Series A financing and public funding backing show financial backing for growth initiatives, enabling sales teams to pursue joint venturing, milestone-based deals, and customer-funded development opportunities.